VLON News and Press, Vallon Pharmaceuticals Inc. From 05/13/21

Vallon Pharmaceuticals (VLON): Q1 net loss of $2.6MCash and cash equivalents of ~$13.0M, which the Company expects will provide funding for its ongoing business activities into the third quarter of 2022.Shares are up 2.67% PM.Press Release For further details see: Vallon Pharm...

- Company remains on track to report p ivotal data from lead program , ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs and indications PHILADELPHIA, PA, May 13, 20...

Vallon Pharmaceuticals (VLON) appoints Leanne Kelly as the company's new chief financial officer. Prior to joining Vallon, Kelly most recently served as the Controller and Executive Director, Global Financial Reporting at OptiNose. Overall, Kelly brings in more than 20 years of...

Vallon Pharmaceuticals (VLON) announces the appointment of Leanne Kelly as the company's chief financial officer.Kelly is a financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sec...

- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (&#...

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stag...

Point Roberts, WA and Delta, BC - April 30, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Tech, Biotech, Mining, Sports and Restaurants. Today's stocks have b...

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on A pril 29 th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon&#x...

Gainers: NovoCure (NVCR) +45%, vTv Therapeutics (VTVT) +28%, Rigel Pharmaceuticals (RIGL) +15%, Zai Lab (ZLAB) +14%, Vallon Pharmaceuticals (VLON) +10%.Losers: Avenue Therapeutics (ATXI) -17%, AdaptHealth (AHCO) -17%, Brook...

Vallon Pharmaceuticals (VLON) provides a clinical program update for its lead program, ADAIR, a abuse-deterrent formulation of immediate-release ((IR)) dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder ((ADHD)) and narcolepsy. “Our...